Skip to content

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

Press Releases

Select Year
Search

Found 144 Results

October 24, 2023

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

October 16, 2023

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

September 7, 2023

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

August 30, 2023

Cognition Therapeutics Announces Participation in Upcoming September Conferences

August 8, 2023

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 2, 2023

Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023

July 11, 2023

Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD

«...6 789 10...20...»

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Email

SEC Filings

Press Releases

End of Day Stock Quote

I accept the Privacy Policy

Loading...

Terms of Use
Privacy Policy
Careers

FCOI Policy
Contact us

Copyright© 2024 Cognition Therapeutics All rights reserved

Scroll to Top